Fever and neutropenia: The early years

Journal of Antimicrobial Chemotherapy

Volumn 63, Issue SUPPL. 1, 2009, Pages

  Bodey, Gerald P ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Acute leukaemia; Antibiotics; Infection; Prophylaxis

Indexed keywords

ANTIINFECTIVE AGENT;

BACTERIAL INFECTION; BLOOD DISEASE; HISTORY; HUMAN; METHODOLOGY; NEUTROPENIA; PATIENT CARE; PYREXIA IDIOPATHICA; REVIEW;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; FEVER OF UNKNOWN ORIGIN; HEMATOLOGIC NEOPLASMS; HISTORY, 20TH CENTURY; HUMANS; NEUTROPENIA; PATIENT ISOLATION;

EID: 79955648673     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp074     Document Type: Article

References (70)

1. Craigie D. Case of disease of the spleen in which death took place in consequence of the presence of purulent matter in the blood. Edinb Med Surg J 1845; 64: 400.
2. Farber S, Diamond LK, Mercer RD et al. Temporary remissions in acute leukemia in children produced by folic acid antagonist 4-amino-pteroyl-glutamic acid (aminopterin). N Engl J Med 1948; 238: 787-93.
3. Dameshek W, Gunz F. Leukemia. 1st Edition. New York: Grune & Stratten, 1958.
4. Boggs DR, Wintrobe MM, Cartwright GE. The acute leukemias. Analysis of 322 cases and review of the literature. Medicine 1962; 41: 163-225.
5. Boggs DR, Frei E III. Clinical studies of fever and infection in cancer. Cancer 1960; 6: 1240-53.
6. Raab SO, Hoeprich PD, Wintrobe MM et al. The clinical significance of fever in acute leukemia. Blood 1960; 16: 1609-28.
7. Silver RT, Utz JP, Frei E III et al. Fever, infection and host resistance in acute leukemia. Am J Med 1958; 24: 25-39.
8. Curtin JA, Marshall BD Jr. Use of antibiotics in cancer and leukemia. J Chronic Dis 1962; 15: 713-8.
9. Frei E III, Freireich EJ. Progress and perspectives in the chemotherapy of acute leukemia. Adv Chemother 1965; 2: 269-98.
10. Gaydos LA, Freireich EJ, Mantel N. The quantitative relation between platelet count and hemorrhage in patients with acute leukemia. N Engl J Med 1962; 266: 905-9.
11. Viola MV. Acute leukemia and infection. JAMA 1967; 201: 923-6.
12. Hersh EM, Bodey GP, Nies BA et al. Causes of death in acute leukemia. A ten year study of 414 patients from 1954-1963. JAMA 1965; 193: 105-9.
13. Bodey GP, Powell RD Jr, Hersh EM et al. Pulmonary complications of acute leukemia. Cancer 1966; 19: 781-93.
14. Stefanini M, Allegra S. Pulmonary mucormycosis in acute histiocytic leukemia. N Engl J Med 1957; 256: 1026-30.
15. Zimmerman LE. Fatal fungus infections complicating other diseases. Am J Clin Pathol 1955; 25: 46-65.
16. Keye JD Jr, Magee WE. Fungal diseases in a general hospital. A study of 88 patients. Am J Clin Pathol 1956; 26: 1235-53.
17. Bodey GP. Fungal infections complicating acute leukemia. J Chronic Dis 1966; 19: 667-87.
18. Bodey GP, Buckley M, Sathe YS et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64: 328-40.
19. Bodey GP, Hersh EM. The problem of infection in children with malignant disease. In: Neoplasia in Childhood. Proc. 12th Annual Clinical Conference at the Univ. of Texas M. D. Anderson Hospital and Tumor Institute at Houston. Chicago, IL: Year Book Medical Publishers, Inc., 1969; 135-54.
20. Sickles EA, Greene WH, Wiernik PH. Clinical presentation of infection in granulocytopenic patients. Arch Intern Med 1975; 135: 715-9.
21. Valdivieso M, Gil-Extremera B, Zornoza J et al. Gram-negative bacillary pneumonia in the compromised host. Medicine 1977; 56: 241-54.
22. Lawson RD, Gentry LO, Bodey GP et al. Randomized study of tobramycin plus ticarcillin, tobramycin plus cephalothin and ticarcillin, or tobramycin plus mezlocillin in the treatment of infection in neutropenic patients with malignancies. Am J Med Sci 1984; 287: 16-23.
23. Freireich EJ, Levin RH, Whang J et al. The function and fate of transfused leukocytes from donors with chronic myelocytic leukemia in leukopenic recipients. Ann N Y Acad Sci 1964; 113: 1081-9.
24. Morse EE, Freireich EJ, Carbone PP et al. The transfusion of leukocytes from donors with chronic myelocytic leukemia to patients with leukopenia. Transfusion 1966; 6: 183-92.
25. Vallejos C, McCredie KB, Bodey GP et al. White blood cell transfusions for control of infections in neutropenic patients. Transfusion 1975; 15: 28-33.
26. Hester JP, Kellogg RM, Mulzet AP et al. Principles of blood separation and component extraction in a disposable continuous-flow single-state channel. Blood 1979; 54: 254-68.
27. Wright DG, Robichaud KJ, Pizzo PA et al. Lethal pulmonary reactions associated with the combined use of amphotericin B and leukocyte transfusions. N Engl J Med 1981; 304: 1185-9.
28. Dana BW, Durie BGM, White RF et al. Concomitant administration of granulocyte transfusions and amphotericin B in neutropenic patients: absence of significant pulmonary toxicity. Blood 1981; 57: 90-4.
29. Winston DJ, Ho WG, Young LS et al. Prophylactic granulocyte transfusions during human bone marrow transplantation. Am J Med 1980; 68: 893-7.
30. Bishton M, Chopra R. The role of granulocyte transfusions in neutropenic patients. Br J Haematol 2004; 127: 501-8.
31. Chanock SJ, Gorlin JB. Granulocyte transfusions. Time for a second look. Infect Dis Clin North Am 1996; 10: 327-43.
32. Hazen JG, Levitan AA, Bourgeois LD. Patient isolator systems in cancer chemotherapy: the use of high-dose 'nonabsorbable' antibiotics in the reduction of bowel flora. Am J Gastroenterol 1968; 50: 195-201.
33. Bodey GP, Freireich EJ, Frei E III. Studies of patients in a laminar air flow unit. Cancer 1969; 24: 972-80.
34. Bodey GP, Johnston D. Microbiological evaluation of protected environments during patient occupancy. Appl Microbiol 1971; 22: 828-36.
35. Bodey GP, Rosenbaum B. Effect of prophylactic measures on the microbial flora of patients in protected environment units. Medicine 1974; 53: 209-28.
36. Klastersky J, Debusscher L, Weerts D et al. Use of oral antibiotics in protected units environment: clinical effectiveness and role in the emergence of antibiotic-resistant strains. Pathol Biol 1974; 22: 5-12.
37. Bodey GP, Rodriguez V. Infections in cancer patients on a protected environment-prophylactic antibiotic program. Am J Med 1975; 59: 497-504.
38. Schimpff SC, Greene WH, Young VM et al. Infection prevention in acute nonlymphocytic leukemia. Ann Intern Med 1975; 82: 351-8.
39. Bodey GP, Gehan EA, Freireich EJ et al. Protected environment- prophylactic antibiotic program in the chemotherapy of acute leukemia. Am J Med Sci 1971; 252: 138-51.
40. Levine AS, Siegel SE, Schreiber AD et al. Protected environments and prophylactic antibiotics. N Engl J Med 1973; 288: 477-83.
41. Yates JW, Holland JF. A controlled study of isolation and endogenous microbial suppression in acute myelocytic leukemia patients. Cancer 1973; 32: 1490-8.
42. Dietrich M, Gaus W, Vossen J et al. Protective isolation and antimicrobial decontamination in patients with high susceptibility to infection. Infection 1977; 5: 107-14.
43. Bodey GP, Rodriguez V, Cabanillas F et al. Protected environment- prophylactic antibiotic program for malignant lymphoma: randomized trial during remission induction chemotherapy. Am J Med 1979; 66: 74-81.
44. Bodey GP, Rodriguez V, Murphy WK et al. Protected environment- prophylactic antibiotic program for malignant sarcomas: randomized trial during remission induction chemotherapy. Cancer 1981; 47: 2422-9.
45. Gurwith MJ, Brunton JL, Lank BA. A prospective controlled investigation of prophylactic trimethoprim/sulfamethoxazole in hospitalized granulocytopenic patients. Am J Med 1979; 66: 248-53.
46. van der Waaij D. The digestive tract in immunocompromised patients: importance of maintaining its resistance to colonization, especially in hospital in-patients and those taking antibiotics. Antonie van Leeuwenhoek 1984; 50: 745-61.
47. Sleijfer DT, Mulder NH, de Vries-Hospers HG et al. Infection prevention in granulocytopenic patients by selective decontamination of the digestive tract. Eur J Cancer 1980; 16: 859-69.
48. de Vries-Hospers HG, Sleijfer DT, Mulder NH et al. Bacteriological aspects of selective decontamination of the digestive tract as a method of infection prevention in granulocytopenic patients. Antimicrob Agents Chemother 1981; 19: 813-20.
49. Bodey GP. Epidemiological studies of Pseudomonas species in patients with leukemia. Am J Med Sci 1970; 260: 82-6.
50. Schimpff SC, Young VM, Greene WH et al. Origin of infection in acute nonlymphocytic leukemia. Significance of hospital acquisition of potential pathogens. Ann Intern Med 1972; 77: 707-14.
51. Fainstein V, Rodriguez V, Turck M et al. Patterns of oropharyngeal and fecal flora in patients with acute leukemia. J Infect Dis 1981; 144: 10-8.
52. Newman KA, Schimpff SC, Young VM et al. Lessons learned from surveillance cultures in patients with acute nonlymphocytic leukemia. Am J Med 1981; 70: 423-31.
53. Forkner CE Jr, Frei E III, Edgcomb JH et al. Pseudomonas septicemia. Observations on twenty-three cases. Am J Med 1958; 25: 877-89.
54. Whitecar JP Jr, Bodey GP, Luna M. Pseudomonas bacteremia in cancer patients. Am J Med Sci 1970; 260: 216-23.
55. Schimpff SC, Greene WH, Young VM et al. Significance of Pseudomonas aeruginosa in the patient with leukemia or lymphoma. J Infect Dis 1974; 130 Suppl: S24-31.
56. Tapper ML, Armstrong D. Bacteremia due to Pseudomonas aeruginosa complicating neoplastic disease. A progress report. J Infect Dis 1974; 130 Suppl: S14-23.
57. Boggs DR, Frei E III, Zierdt CH. Fever in malignant neoplastic disease: a controlled study of tetracycline therapy. Ann Intern Med 1960; 53: 754-64.
58. Bodey GP, Nies BA, Mohberg NR et al. Use of gamma globulin in infection in acute leukemia patients. JAMA 1964; 190: 1099-102.
59. Bodey GP, Nies BA, Mohberg NR et al. The effect of adrenal corticosteroid therapy on infections in acute leukemia. Am J Med Sci 1965; 250: 162-7.
60. Rodriguez V, Stewart D, Bodey GP. Gentamicin sulfate distribution in body fluids. J Clin Pharmacol Ther 1970; 11: 275-81.
61. Bodey GP, Middleman E, Umsawasdi T et al. Infections in cancer patients-results with gentamicin sulfate therapy. Cancer 1972; 29: 1697-701.
62. Bodey GP, Rodriguez V, Stewart D. Clinical pharmacological studies of carbenicillin. Am J Med Sci 1969; 257: 185-90.
63. Bodey GP, Whitecar JP Jr, Middleman E et al. Carbenicillin therapy of Pseudomonas infections. JAMA 1971; 218: 62-6.
64. Middleman EA, Watanabe A, Kaizer H et al. Antibiotic combinations for infections in neutropenic patients. Evaluation of carbenicillin plus either cephalothin or kanamycin. Cancer 1972; 30: 573-9.
65. Schimpff S, Satterlee W, Young VM et al. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med 1971; 284: 1061-5.
66. The EORTC International Antimicrobial Therapy Project Group. Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer. J Infect Dis 1978; 137: 14-29.
67. Klasterskly J, Vamecq G, Cappel R et al. Effects of the combination of gentamicin and carbenicillin on the bactericidal activity of serum. J Infect Dis 1972; 125: 183-6.
68. Bodey GP, Jadeja L, Elting L. Pseudomonas bacteremia. Arch Intern Med 1985; 145: 1621-9.
69. De Pauw BE, Kauw F, Muytjens H et al. Randomized study of ceftazidime versus gentamicin plus cefotaxime for infections in severe granulocytopenic patients. J Antimicrob Chemother 1983; 12 Suppl A: 93-9.
70. De Pauw B, Williams K, de Neeff J et al. A randomized prospective study of ceftazidime versus ceftazidime plus flucloxacillin in the empiric treatment of febrile episodes in severely neutropenic patients. Antimicrob Agents Chemother 1985; 28: 824-8.